{"pmid":32292907,"pmcid":"PMC7147214","title":"Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.","text":["Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.","Med Drug Discov","Janda, Kim D","Iadarola, Michael J","32292907"],"journal":"Med Drug Discov","authors":["Janda, Kim D","Iadarola, Michael J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292907","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.medidd.2020.100034","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266295697211392,"score":8.233237,"similar":[{"pmid":32283315,"pmcid":"PMC7151236","title":"COVID-19 or Lung Cancer: what should we treat?","text":["COVID-19 or Lung Cancer: what should we treat?","J Thorac Oncol","Russano, Marco","Citarella, Fabrizio","Vincenzi, Bruno","Tonini, Giuseppe","Santini, Daniele","32283315"],"journal":"J Thorac Oncol","authors":["Russano, Marco","Citarella, Fabrizio","Vincenzi, Bruno","Tonini, Giuseppe","Santini, Daniele"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283315","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jtho.2020.04.001","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664182200798543873,"score":57.825573},{"pmid":32220930,"title":"Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.","text":["Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.","Clin J Am Soc Nephrol","Sparks, Matthew A","South, Andrew","Welling, Paul","Luther, J Matt","Cohen, Jordana","Byrd, James Brian","Burrell, Louise M","Batlle, Daniel","Tomlinson, Laurie","Bhalla, Vivek","Rheault, Michelle N","Soler, Maria Jose","Swaminathan, Sundar","Hiremath, Swapnil","32220930"],"journal":"Clin J Am Soc Nephrol","authors":["Sparks, Matthew A","South, Andrew","Welling, Paul","Luther, J Matt","Cohen, Jordana","Byrd, James Brian","Burrell, Louise M","Batlle, Daniel","Tomlinson, Laurie","Bhalla, Vivek","Rheault, Michelle N","Soler, Maria Jose","Swaminathan, Sundar","Hiremath, Swapnil"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220930","week":"202014|Mar 30 - Apr 05","doi":"10.2215/CJN.03530320","keywords":["ACE inhibitors","Angiotensin-Converting Enzyme Inhibitors","COVID-19","Renin-Angiotensin System","angiotensin","hypertension","renin angiotensin system","severe acute respiratory syndrome coronavirus 2","virology"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135184547840,"score":56.370766},{"pmid":32203970,"title":"Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade.","text":["Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade.","Here, we review the most recent findings on the effects of SARS-CoV-2 infection on kidney diseases, including acute kidney injury, and examine the potential effects of ARBs on the outcomes of patients with COVID-19. Lastly, we discuss the clinical management of COVID-19 patients with existing chronic renal disorders, particularly those in dialysis and with kidney transplants.","Nephron","Perico, Luca","Benigni, Ariela","Remuzzi, Giuseppe","32203970"],"abstract":["Here, we review the most recent findings on the effects of SARS-CoV-2 infection on kidney diseases, including acute kidney injury, and examine the potential effects of ARBs on the outcomes of patients with COVID-19. Lastly, we discuss the clinical management of COVID-19 patients with existing chronic renal disorders, particularly those in dialysis and with kidney transplants."],"journal":"Nephron","authors":["Perico, Luca","Benigni, Ariela","Remuzzi, Giuseppe"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203970","week":"202013|Mar 23 - Mar 29","doi":"10.1159/000507305","keywords":["Angiotensin receptor blockers","Angiotensin-converting enzyme inhibitors","COVID-19","Renal and cardiac side effects","SARS-CoV-2","Severe acute respiratory syndrome coronavirus"],"source":"PubMed","topics":["Mechanism","Transmission","Treatment"],"weight":1,"_version_":1663352133637898242,"score":54.09462},{"pmid":32133825,"title":"[Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19].","text":["[Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19].","Zhonghua Xue Ye Xue Za Zhi","Mei, H","Hu, Y","32133825"],"journal":"Zhonghua Xue Ye Xue Za Zhi","authors":["Mei, H","Hu, Y"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32133825","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.issn.0253-2727.2020.0002","source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352134232440832,"score":47.32526},{"pmid":32274342,"pmcid":"PMC7132016","title":"COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies.","text":["COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies.","The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19.","J Clin Transl Hepatol","Feng, Gong","Zheng, Kenneth I","Yan, Qin-Qin","Rios, Rafael S","Targher, Giovanni","Byrne, Christopher D","Poucke, Sven Van","Liu, Wen-Yue","Zheng, Ming-Hua","32274342"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19."],"journal":"J Clin Transl Hepatol","authors":["Feng, Gong","Zheng, Kenneth I","Yan, Qin-Qin","Rios, Rafael S","Targher, Giovanni","Byrne, Christopher D","Poucke, Sven Van","Liu, Wen-Yue","Zheng, Ming-Hua"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274342","week":"202015|Apr 06 - Apr 12","doi":"10.14218/JCTH.2020.00018","keywords":["COVID-19","Liver dysfunction","SARS-CoV-2"],"source":"PubMed","topics":["Treatment","Prevention","Diagnosis"],"weight":1,"e_drugs":["Aspartic Acid"],"_version_":1663712077857947648,"score":47.32526}]}